Atai Life Sciences N.V.

XTRA:9VC Stock Report

Market Cap: €191.4m

Atai Life Sciences Valuation

Is 9VC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9VC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9VC?

Key metric: As 9VC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9VC. This is calculated by dividing 9VC's market cap by their current book value.
What is 9VC's PB Ratio?
PB Ratio1.4x
BookUS$145.72m
Market CapUS$199.68m

Price to Book Ratio vs Peers

How does 9VC's PB Ratio compare to its peers?

The above table shows the PB ratio for 9VC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.9x
APPH Apontis Pharma
2.7x78.1%€84.1m
PSG PharmaSGP Holding
7.7x13.6%€283.0m
2FJ0 Pierrel
3.6xn/a€92.8m
HIGH Cantourage Group
1.4x114.7%€64.2m
9VC Atai Life Sciences
1.4x34.6%€199.7m

Price-To-Book vs Peers: 9VC is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (3.9x).

Price to Book Ratio vs Industry

How does 9VC's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
9VC 1.4xIndustry Avg. 2.2xNo. of Companies14PB01.63.24.86.48+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 9VC is good value based on its Price-To-Book Ratio (1.4x) compared to the European Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 9VC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9VC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9VC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9VC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.15
€7.55
+558.0%
31.9%€10.39€4.72n/a4
Dec ’25€1.66
€7.55
+354.2%
31.9%€10.39€4.72n/a4
Nov ’25€0.99
€8.37
+744.5%
43.5%€13.57€4.52n/a4
Oct ’25€1.01
€8.37
+730.7%
43.5%€13.57€4.52n/a4
Sep ’25€1.18
€8.37
+609.3%
43.5%€13.57€4.52n/a4
Aug ’25€1.39
€8.77
+533.0%
39.7%€13.85€5.54n/a4
Jul ’25€1.23
€10.89
+788.4%
48.4%€19.38€5.54n/a5
Jun ’25€1.45
€10.89
+653.2%
48.4%€19.38€5.54n/a5
May ’25€1.83
€10.89
+495.5%
48.4%€19.38€5.54n/a5
Apr ’25€1.82
€13.36
+634.0%
43.2%€19.34€5.53n/a4
Mar ’25€1.86
€11.58
+521.9%
53.5%€19.26€4.68n/a5
Feb ’25€1.65
€11.58
+603.1%
53.5%€19.26€4.68n/a5
Jan ’25€1.39
€11.58
+735.2%
53.5%€19.26€4.68n/a5
Dec ’24€1.02
€11.39
+1,020.1%
50.1%€19.36€4.70€1.666
Nov ’24€1.16
€11.38
+878.7%
47.3%€19.65€4.77€0.997
Oct ’24€1.23
€11.38
+822.4%
47.3%€19.65€4.77€1.017
Sep ’24€1.41
€10.55
+648.7%
49.0%€19.25€4.67€1.188
Aug ’24€1.87
€11.05
+492.4%
40.9%€18.93€4.60€1.3910
Jul ’24€1.46
€11.04
+658.0%
40.7%€19.37€4.70€1.2311
Jun ’24€1.64
€11.04
+571.5%
40.7%€19.37€4.70€1.4511
May ’24€1.74
€10.86
+522.7%
40.7%€19.06€4.63€1.8311
Apr ’24€1.56
€10.96
+602.5%
39.1%€19.37€4.70€1.8212
Mar ’24€1.50
€11.74
+680.4%
37.3%€19.38€4.71€1.8612
Feb ’24€1.63
€11.74
+621.9%
37.3%€19.38€4.71€1.6512
Jan ’24€2.32
€20.77
+795.2%
46.1%€47.11€6.22€1.3913
Dec ’23€3.21
€22.70
+607.0%
46.9%€49.06€6.48€1.0212

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atai Life Sciences N.V. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.